Immunotherapy with DNA vaccine shows promise for HPV-related head and neck cancer

(University of Pennsylvania School of Medicine) A novel vaccine therapy can generate immune responses in patients with head and neck squamous cell carcinoma (HNSCCa), according to researchers at the Abramson Cancer Center of the University of Pennsylvania. The treatment specifically targets human papillomavirus (HPV), which is frequently associated with HNSCCa, to trigger the immune response. Researchers will present the results of their pilot study during the 2017 American Society of Clinical Oncology Annual Meeting in Chicago (Abstract #6073).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news